XML 44 R32.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue (Disaggregation of Revenue by Product) (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Disaggregation of Revenue [Line Items]    
Revenue $ 6,805.6 $ 5,859.8
U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 3,941.3 3,328.8
Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 2,864.3 2,531.0
Diabetes    
Disaggregation of Revenue [Line Items]    
Revenue 3,111.1 2,968.9
Diabetes | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 2,061.2 1,991.2
Diabetes | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 1,049.9 977.7
Trulicity®    
Disaggregation of Revenue [Line Items]    
Revenue 1,452.4 1,229.4
Trulicity® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 1,116.8 929.5
Trulicity® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 335.7 299.9
Humalog®    
Disaggregation of Revenue [Line Items]    
Revenue 617.0 695.8
Humalog® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 332.7 398.6
Humalog® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 284.4 297.2
Humulin®    
Disaggregation of Revenue [Line Items]    
Revenue 321.7 315.7
Humulin® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 219.0 214.1
Humulin® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 102.7 101.5
Jardiance    
Disaggregation of Revenue [Line Items]    
Revenue 312.0 267.5
Jardiance | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 151.2 144.6
Jardiance | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 160.8 122.9
Basaglar®    
Disaggregation of Revenue [Line Items]    
Revenue 246.6 303.7
Basaglar® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 175.2 230.4
Basaglar® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 71.4 73.3
Other Diabetes    
Disaggregation of Revenue [Line Items]    
Revenue 161.4 156.8
Other Diabetes | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 66.3 74.0
Other Diabetes | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 94.9 82.9
Oncology    
Disaggregation of Revenue [Line Items]    
Revenue 1,372.2 1,201.5
Oncology | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 642.5 657.9
Oncology | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 729.7 543.6
Alimta®    
Disaggregation of Revenue [Line Items]    
Revenue 559.0 560.1
Alimta® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 261.1 324.2
Alimta® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 297.8 235.8
Verzenio®    
Disaggregation of Revenue [Line Items]    
Revenue 269.0 188.0
Verzenio® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 172.8 129.4
Verzenio® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 96.2 58.6
Cyramza®    
Disaggregation of Revenue [Line Items]    
Revenue 240.5 239.0
Cyramza® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 80.2 89.1
Cyramza® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 160.3 149.9
Erbitux®    
Disaggregation of Revenue [Line Items]    
Revenue 122.4 130.8
Erbitux® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 107.9 117.8
Erbitux® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 14.4 13.0
Tyvyt®    
Disaggregation of Revenue [Line Items]    
Revenue 109.7 57.4
Tyvyt® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 0.0 0.0
Tyvyt® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 109.7 57.4
Other Oncology    
Disaggregation of Revenue [Line Items]    
Revenue 71.6 26.2
Other Oncology | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 20.5 (2.6)
Other Oncology | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 51.3 28.9
Immunology    
Disaggregation of Revenue [Line Items]    
Revenue 613.9 585.8
Immunology | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 284.8 341.4
Immunology | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 329.1 244.4
Taltz®    
Disaggregation of Revenue [Line Items]    
Revenue 403.2 443.5
Taltz® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 249.6 327.5
Taltz® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 153.6 116.0
Olumiant®    
Disaggregation of Revenue [Line Items]    
Revenue 193.8 139.7
Olumiant® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 24.7 11.3
Olumiant® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 169.1 128.4
Other Immunology    
Disaggregation of Revenue [Line Items]    
Revenue 16.9 2.6
Other Immunology | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 10.5 2.6
Other Immunology | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 6.4 0.0
Neuroscience    
Disaggregation of Revenue [Line Items]    
Revenue 465.4 463.5
Neuroscience | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 141.7 110.3
Neuroscience | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 323.7 353.2
Cymbalta®    
Disaggregation of Revenue [Line Items]    
Revenue 176.6 210.4
Cymbalta® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 11.0 11.6
Cymbalta® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 165.7 198.8
Emgality®    
Disaggregation of Revenue [Line Items]    
Revenue 119.5 74.0
Emgality® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 101.5 67.3
Emgality® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 18.0 6.7
Zyprexa®    
Disaggregation of Revenue [Line Items]    
Revenue 95.8 98.4
Zyprexa® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 6.9 11.2
Zyprexa® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 88.9 87.2
Other Neuroscience    
Disaggregation of Revenue [Line Items]    
Revenue 73.5 80.7
Other Neuroscience | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 22.3 20.2
Other Neuroscience | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 51.1 60.5
Other    
Disaggregation of Revenue [Line Items]    
Revenue 1,242.9 640.1
Other | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 811.1 228.0
Other | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 431.8 412.1
COVID-19 Antibodies    
Disaggregation of Revenue [Line Items]    
Revenue 810.1 0.0
COVID-19 Antibodies | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 650.6 0.0
COVID-19 Antibodies | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 159.5 0.0
Forteo®    
Disaggregation of Revenue [Line Items]    
Revenue 198.5 272.4
Forteo® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 97.7 122.5
Forteo® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 100.8 149.8
Cialis®    
Disaggregation of Revenue [Line Items]    
Revenue 126.8 193.0
Cialis® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 8.6 26.1
Cialis® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 118.1 167.0
Other    
Disaggregation of Revenue [Line Items]    
Revenue 107.5 174.7
Other | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 54.2 79.4
Other | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue $ 53.4 $ 95.3